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Accepted 22 April 2013Inadequate mobilization of peripheral blood progenitor cells (PBPC) is sometimes a limiting factor to proceed
with an autologous hematopoietic cell transplantation (auto-HCT), in an otherwise eligible patient. In such
situations, a bone marrow harvest (BMH) procedure may be considered to achieve the CD34þ target dose for
an autograft. Plerixafor-based mobilization has recently been shown to improve PBPC collection yields.
However, the feasibility and outcomes of BMH in patients failing plerixafor-based mobilization is not known.
We report here, 6 patients who underwent BMH after PBPC mobilization failure with plerixafor. The median
CD34þ yield with plerixafor mobilization and BMH were 1.15 x 10^6/Kg (range, 0.2-1.7  10^6/Kg) and 0.32
(range, 0.12-0.38  10^6/Kg), respectively. Three patients proceeded to an auto-HCT, with only 1 patient
receiving CD34þ cell dose of at least 2  10^6/Kg. While neutrophil recovery was seen, platelet recovery and
red cell transfusion independence were delayed. All 3 autografted patients experienced disease progression
by day +100. These data suggest, limited incremental beneﬁt of a salvage BMH after plerixafor mobilization
failure, cautioning against routine use of this strategy.
 2013 American Society for Blood and Marrow Transplantation.Peripheral blood stem and progenitor cell (PBPC) mobili-
zation failure frequently prevents patientswith hematologicalmalignancies from undergoing a planned autologous hema-
topoietic cell transplantation (auto-HCT) procedure [1]. The
combination of plerixafor and granulocyte colony-stimulating
factor (G-CSF) has been shown to improve PBPC collection
yield and potentially reduce mobilization failure rates in
non-Hodgkin lymphoma and multiple myeloma compared
with mobilization with G-CSF alone [2,3]. Limited data
also suggest safety and feasibility of plerixafor salvage in
patients who appear to be failing chemotherapy-based
mobilization [4,5].
Table 1
Baseline Patient Characteristics
UPN Sex Age at
Mobilization (yr)
Diagnosis Stage BM
Involved*
Premobilization
Platelets < 100  109/L
Number of Prior
Therapies
Prior Radiation (Site) Disease Status
1 Female 56 MCL 4 Yes Yes 1 No CR1
2 Male 72 DLBCL 3 No No 2 No CR2
3 Male 58 PCNSL - No No 3 Yes (brain) PR2
4 Male 56 HL 3 No No 2 No PD
5 Female 62 DLBCL 4 Yes Yes 2 No PR2
6 Female 49 DLBCL 1 No No 4 Yes (mediastinum) CR2
MCL indicates mantle cell lymphoma; DLBCL, diffuse large B cell lymphoma; PCNSL, primary central nervous system lymphoma; HL, Hodgkin lymphoma; BM,
bone marrow; CR, complete remission; PD, progressive disease; PR, partial remission.
* Bone marrow involvement at diagnosis (UPN 1) and at the time of ﬁrst relapse (UPN 5).
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graft source for auto-HCT and is associated with faster
engraftment kinetics and earlier transfusion independence
[6], a salvage bone marrow harvest (BMH) to supplement
a suboptimal PBPC yield after a G-CSFeonly mobilization is
sometimes considered to provide patients access to auto-
HCT [7]. However, the feasibility of salvage BMH in patients
failing a plerixafor-based mobilization attempt is not known.
We report here outcomes of 6 lymphoid malignancy patients
who failed plerixafor-based mobilization and then subse-
quently underwent salvage BMH.
Baseline characteristics of the 6 patients are shown in
Table 1. Patient median age was 57 years (range, 49 to 72).
Two patients each had premobilization thrombocytopenia,
deﬁned as platelet count < 100  109/L (unique patient
number [UPN] 1 and 5) and prior radiation exposure (UPN 3
and 6). Although 2 patients (UPN 1 and 5) had history of
disease involving the bone marrow, their premobilization
bone marrow evaluation showed no evidence of persistent
disease. Three patients (UPN 1, 5, and 6) had hypocellular
marrow for age at mobilization without any evidence of
dysplastic changes; 20%, 15%, and 15% respectively. All
patients except UPN 4 had chemosensitive disease.
To mobilize PBPC, G-CSF and plerixafor were adminis-
tered as previously described [5]. Apheresis was routinely
initiated when peripheral blood CD34þ count was at least
10/mL. All collections were performed with a COBE Spectra
Apheresis System (CaridianBCT, Lakewood, CO) by process-
ing 3 to 4 blood volumes each day. The target optimal CD34þ
cell yield at our institution is at least 5  106/kg recipient
body weight, whereas a minimum dose of at least 2  106/kg
is recommended to proceed with auto-HCT. Patients not
collecting the minimum CD34þ cell dose are considered forTable 2
Results of Plerixafor/G-CSF Mobilization and Bone Marrow Harvest
UPN Peak PB
CD34
(/mL)
No. of
Apheresis
Sessions
PB TNC Yield
(108/kg
ABW)
PB CD34þ
Yield (106/kg
ABW)
BM Harvest
TNC Yield
(108/kg
ABW)
BM Harv
CD34þ Y
(106/k
ABW)
1z 2 2 5.4 .2 1.4 .28
2x 7 3 26.6 1.4 .59 .12
3 12 4 25.3 1.1 1.26 .38
4 11 3 23.4 1.7 1.8 .37
5 11 2 13.2 1.2 1.34 .13
6 3 3 9.2 .6 1.9 .36
PB indicates peripheral blood; TNC, total nucleated cells; BM, bone marrow; ABW,
* Total TNC and CD34 yield is deﬁned as the respective sums of peripheral bloo
y Overall survival deﬁned as months alive from date of autograft to death/last foll
to death/last follow-up for those who did not undergo auto-HCT.
z This patient underwent a prior mobilization attempt with cyclophosphamid
peripheral blood CD34þ count was only 1.4/mL.
x This patient did not undergo auto-HCT considering his advanced age and conc
discretion of treating physician.BMH at the treating physician’s discretion. BMH was per-
formed in the operating room following the transplantation
program’s standard operating procedures.
Brieﬂy, the patient was placed in the prone position on
a supportive frame allowing posterior iliac crests to be
prominent. To aspirate bone marrow from bilateral iliac
crests, needles with trochar were inserted into the iliac
crests. Bone marrow was aspirated using heparinized 50-mL
syringes. Five to 10mL of bonemarrowwas aspirated in each
attempt and emptied into a heparinized collecting bag. The
collection bag was agitated by gentle squeezing throughout
the harvest to ensure uniform distribution of anticoagulant.
After each aspirate, the needle was reinserted via the same
skin site but repositioned to a new bone site. After collecting
approximately 400 to 500 mL of bone marrow, a 1-mL
syringe sample from the collecting bag was obtained to
measure the nucleated cell count. This number was used to
determine the volume of BMH, using the patient’s body
weight as a reference. Upon completion of the BMH proce-
dure, the product was ﬁltered using a sterile closed-system
commercially available kit and transported to the apheresis
laboratory. No priming with growth factors was used before
BMH.
Table 2 describes the results of PBPCmobilization attempt
with plerixafor/G-CSF and subsequent BMH in all 6 patients.
Only UPN 1 had a previous mobilization attempt with
cyclophosphamide/G-CSF but did not undergo apheresis at
that time because of low peak peripheral blood CD34þ cell
count (1.4/mL). Peak peripheral blood CD34þ cell count was
at least 10/mL in 3 patients after plerixafor mobilization. The
median number of apheresis sessions was 3 (range, 2 to 4).
The median CD34þ cell yield after peripheral blood mobili-
zationwas 1.15106/kg (range, 0.2 to 1.7 106/kg). After theest
ield
g
Total* TNC
Yield (108/kg
ABW)
Total* CD34
Yield (106/kg
ABW)
Received
Auto-
HCT
Days to
Neutrophil,
Platelet
Recovery
Overall
Survivaly
(mo)
6.8 .48 No NA 23 (alive)
27.19 1.52 No NA 22 (alive)
26.56 1.48 Yes 14, 22 16 (dead)
25.2 2.07 Yes 15, NR 14 (alive)
14.66 1.33 Yes 18, 65 6 (dead)
10.1 .96 No NA 2 (alive)
actual patient body weight; NA, not applicable; NR, not recovered at 1 year.
d and bone marrow harvest yields.
ow-up for transplanted patients andmonths alive frommobilization attempt
e þ G-CSF mobilization but did not undergo apheresis because the peak
erns about infectious complications with a low progenitor cell dose, at the
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nucleated cell count of 2  108/kg. The median CD34þ cell
count obtained by BMH was .32 (range, .12 to .38  106/kg).
The combined (PBPCþBMH) median CD34þ yield was 1.4
(range, .48 to 2.07  106/kg), with only 1 patient (UPN 4)
achieving CD34þ dose of at least 2  106/kg.
Three patients (UPN 3, 4, and 5) proceeded to auto-HCT
receiving a total CD34þ cell dose of 1.48, 2.07, and 1.33
(106/kg), respectively. All 3 received high-dose therapy
with CBV (cyclophosphamide þ carmustine þ etoposide)
before autograft, followed by G-CSF support starting on
day þ5 posttransplantation. The median time to neutrophil
engraftment (absolute neutrophil count  0.5  109/L) was
15 days (range, 14 to 18). UPN 3 and 5 had platelet recovery
(>20  109/L) by day þ22 and þ65, respectively, whereas
UPN 4 did not achieve platelet engraftment by 1 year after
auto-HCT. Red blood cell transfusion independence was
achieved by UPN 3 and 5 by day þ9 and þ42, respectively,
whereas persistent anemia was noted in UPN 4 (hemoglobin
8.3 g/dL at 1 year). All 3 patients had disease progression
before day þ100. One patient (UPN 4) was alive at last
follow-up; UPN 3 and 5 died at 16 and 6 months after auto-
HCT, respectively.
In this case series, 6 patients with lymphoid malignancies
eligible for auto-HCT underwent a salvage BMH to supple-
ment a prior failed PBPC collection attempt with plerixafor
and G-CSF. Sinitsyn et al. [7] reported the results of 19
patients who underwent a combined PBPC collection with
G-CSF alone and subsequent BMH to obtain a median CD34þ
cell dose of 2.2  106/kg but did not include plerixafor
mobilization. In comparison, we report the ﬁrst case series
describing the feasibility of BMH after an unsuccessful
mobilization attempt with a plerixafor-based strategy. In our
series, all but 1 patient failed to achieve a combined CD34þ
cell dose of at least 2  106 CD34þ cells/kg, suggesting
minimal incremental beneﬁt of a salvage BMH in patients
failing a plerixafor-based mobilization attempt. Although 3
patients did undergo auto-HCT in our experience, 2 of them
received CD34þ cell doses of <1.5  106 cells/kg. All 3
patients had neutrophil recovery comparable with prior
reports with low infused CD34þ cell doses [7,8]. The platelet
recovery was delayed in 2 patients, and at least 1 patient was
red blood cell transfusion dependent at 1 year. All 3 patients
had early disease progression, and only 1 patient survived
beyond 18 months. Others have previously reported poor
auto-HCT outcomes in poor mobilizers [9,10]. It is probable
that poor mobilization is a surrogate marker for higher-risk
disease and increased lines of prior therapies.Although acknowledging the small sample size, the need
for further validation, and the inherent bias of our retro-
spective analysis, it appears that a salvage BMH in patients
failing a plerixafor-based PBPC mobilization provides little or
no sustained clinical beneﬁt. Our data caution against the
routine use of BMH in patients failing plerixafor-based PBPC
mobilization. If available, enrolling patients failing plerixafor-
based mobilization on any available trials investigating novel
mobilization strategies should be considered, or, alterna-
tively, evaluation of these patients for allogeneic trans-
plantation on case-by-case basis is warranted.
ACKNOWLEDGMENTS
Financial disclosure: The authors have nothing to disclose.
REFERENCES
1. Olivieri A, Brunori M, Capelli D, et al. Salvage therapy with an outpa-
tient DHAP schedule followed by PBSC transplantation in 79 lymphoma
patients: an intention to mobilize and transplant analysis. Eur J
Haematol. 2004;72:10-17.
2. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF
versus placebo and G-CSF to mobilize hematopoietic stem cells for
autologous stem cell transplantation in patients with multiple
myeloma. Blood. 2009;113:5720-5726.
3. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Phase III prospective
randomized double-blind placebo-controlled trial of plerixafor plus
granulocyte colony-stimulating factor compared with placebo plus
granulocyte colony-stimulating factor for autologous stem-cell mobi-
lization and transplantation for patients with non-Hodgkin’s
lymphoma. J Clin Oncol. 2009;27:4767-4773.
4. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can
successfully mobilize CD34þ cells from non-Hodgkin’s lymphoma,
Hodgkin’s disease and multiple myeloma patients previously
failing mobilization with chemotherapy and/or cytokine treatment:
compassionate use data. Bone Marrow Transplant. 2008;41:331-338.
5. Awan FT, Kochuparambil ST, DeRemer D, et al. Plerixafor salvage is safe
and effective in hard-to-mobilize patients undergoing chemotherapy
and ﬁlgrastim-based peripheral blood progenitor cell mobilization.
J Oncol. 2012;2012:931071.
6. Schmitz N, Dreger P, Linch DC, et al. Randomized trial of ﬁlgrastim-
mobilised peripheral blood progenitor cell transplantation versus
autologous bone-marrow transplantation in lymphoma patients.
Lancet. 1996;347:353-357.
7. Sinitsyn Y, Malone A, Mandeli J, et al. Combined bone marrow and
peripheral blood progenitor cell autografts for patients with poor
mobilization. Cytotherapy. 2009;11:457-463.
8. Stockerl-Goldstein KE, Reddy SA, Horning S, et al. Favorable treatment
outcome in non-Hodgkin’s lymphoma patients with “poor” mobiliza-
tion of peripheral blood progenitor cells. Biol Blood Marrow Transplant.
2000;6:506-512.
9. Tomblyn M, Burns LJ, Blazar B, et al. Difﬁcult stem cell mobilization
despite adequate CD34þ cell dose predicts shortened progression free
and overall survival after autologous HSCT for lymphoma. Bone Marrow
Transplant. 2007;40:111-118.
10. Gordan LN, Sugrue MW, Lynch JW, et al. Poor mobilization of
peripheral blood stem cells is a risk factor for worse outcome in
lymphoma patients undergoing autologous stem cell transplantation.
Leuk Lymph. 2003;44:815-820.
